Innoviva (INVA) has wrapped up FY 2025 with Q4 revenue of US$114.6 million and basic EPS of US$2.19, capping a trailing 12 month period where revenue was US$411.3 million and basic EPS reached US$4.02 alongside a reported net profit margin of 65.9% that was lifted by a US$161.6 million one off gain. Over the past few quarters, the company has seen revenue move from US$88.6 million in Q1 2025 to US$114.6 million in Q4 2025, while basic EPS shifted from a loss of US$0.74 in Q1 2025 to US$2.19 in Q4 2025. This sets up a results season in which investors are likely to focus on how durable these margins are.
See our full analysis for Innoviva.With the headline numbers on the table, the next step is to see how they line up with the widely held narratives about Innoviva, and where the recent margin profile might challenge those views.
Curious how numbers become stories that shape markets? Explore Community Narratives
Q4 profit swings from Q1 loss to US$164.2 million
- Across FY 2025, net income moved from a loss of US$46.6 million in Q1 to US$164.2 million in Q4, with the trailing 12 month net income at US$271.2 million, so the full year picture is very different from how the year started.
- What stands out for a bullish take is how the trailing 12 month basic EPS reached US$4.02 and net profit margin was reported at 65.9%, yet this sits next to a five year annualised earnings decline of 22.1%. This means:
- Supporters who focus on the recent turnaround can point to Q2 to Q4 basic EPS between roughly US$1.01 and US$2.19 as evidence that profitability has held above early 2024 levels in recent quarters.
- The longer term decline in earnings growth rate, despite the strong trailing 12 month print, shows the bullish story is relying heavily on the latest year rather than a multi year pattern.
Strong recent profits sit next to a weaker multi year track record, and that tension is exactly what many investors are trying to weigh up right now. 📊 Read the what the Community is saying about Innoviva.
One off gain inflates 65.9% margin
- The reported 65.9% trailing net profit margin is much higher than the 6.5% margin a year earlier, and the data attributes a US$161.6 million one off gain as a key factor, so a large slice of the margin is tied to a single item rather than repeatable operations.
- Critics highlight that the very large year over year earnings improvement, described as more than a tenfold jump, is hard to treat as a new normal when:
- The one off gain of US$161.6 million fed directly into the trailing 12 month net income of US$271.2 million, which means a material portion of that profit is non recurring.
- The same data set shows analysts expecting earnings to decline by about 0.8% per year over the next three years, so the bearish view is that the spike in margins does not line up with the more muted outlook.
“Cheap” 6.5x P/E versus 19.9x industry
- At a share price of US$23.54, the trailing P/E of 6.5x sits well below both the reported US Pharmaceuticals industry average of 19.9x and a peer average of 17.7x, while the DCF fair value cited for Innoviva is US$53.96, which is much higher than the current price.
- What is interesting for the more cautious, bearish narrative is that this discount exists alongside softer longer term earnings trends and forecasts:
- Earnings across the last five years declined at about 22.1% per year, even though the most recent trailing 12 month period shows very strong profit, so the low P/E is being judged on a high earnings base that includes a large one off gain.
- Revenue is forecast to grow at 9.5% per year, slightly below the 10.4% reference rate for the US market, which bears use to argue that the apparent valuation gap may be partly explained by more modest growth expectations.
If you want to see how other investors are weighing that low 6.5x P/E against the earnings record and forecasts, the community discussion is a helpful next step. Curious how numbers become stories that shape markets? Explore Community Narratives
Next Steps
Don't just look at this quarter; the real story is in the long-term trend. We've done an in-depth analysis on Innoviva's growth and its valuation to see if today's price is a bargain. Add the company to your watchlist or portfolio now so you don't miss the next big move.
If the mixed signals in this story have you on the fence, it is worth checking the numbers yourself and forming a clear view quickly. You can weigh the tension between concerns and optimism by looking at 3 key rewards and 3 important warning signs for this company and seeing which side of the story matters more to you.
See What Else Is Out There
Innoviva’s reliance on a one off US$161.6 million gain, a five year annualised earnings decline of 22.1%, and softer forecasts raises questions about consistency.
If that patchy earnings record has you looking for steadier stories, check out 80 resilient stocks with low risk scores today to focus on companies with more resilient profiles.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com